PE20230494A1 - Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas - Google Patents

Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas

Info

Publication number
PE20230494A1
PE20230494A1 PE2022002607A PE2022002607A PE20230494A1 PE 20230494 A1 PE20230494 A1 PE 20230494A1 PE 2022002607 A PE2022002607 A PE 2022002607A PE 2022002607 A PE2022002607 A PE 2022002607A PE 20230494 A1 PE20230494 A1 PE 20230494A1
Authority
PE
Peru
Prior art keywords
proteins
baff
april
methods
immunomodulatory proteins
Prior art date
Application number
PE2022002607A
Other languages
English (en)
Inventor
Stacey Dillon
Mark Rixon
Lawrence Evans
Daniel William Demonte
Joseph L Kuijper
Stanford L Peng
Original Assignee
Alpine Immune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpine Immune Sciences Inc filed Critical Alpine Immune Sciences Inc
Publication of PE20230494A1 publication Critical patent/PE20230494A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

En la presente se proporcionan proteinas inmunomoduladoras que exhiben actividad neutralizante de BAFF y APRIL (o heterotrimeros de BAFF/APRIL). Las proteinas inmunomoduladoras proporcionadas en la presente incluyen dominios variantes de Activador Transmembrana e Interactor de CAML (TACI). Entre las proteinas inmunomoduladoras proporcionadas estan las proteinas de fusion de TACI-Fc. Tambien se proporcionan moleculas de acido nucleico que codifican para las proteinas inmunomoduladoras. Las proteinas inmunomoduladoras proporcionan utilidad terapeutica para una variedad de enfermedades, trastornos o condiciones inmunologicas. Tambien se proporcionan composiciones y metodos para producir y utilizar estas proteinas
PE2022002607A 2020-05-08 2021-05-07 Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas PE20230494A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063022373P 2020-05-08 2020-05-08
US202063034361P 2020-06-03 2020-06-03
US202063080643P 2020-09-18 2020-09-18
PCT/US2021/031430 WO2021226551A1 (en) 2020-05-08 2021-05-07 April and baff inhibitory immunomodulatory proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20230494A1 true PE20230494A1 (es) 2023-03-23

Family

ID=76270049

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002607A PE20230494A1 (es) 2020-05-08 2021-05-07 Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas

Country Status (15)

Country Link
US (3) US20210388054A1 (es)
EP (2) EP4146684A2 (es)
JP (2) JP2023525032A (es)
KR (2) KR20230029622A (es)
CN (4) CN117736297A (es)
AU (2) AU2021267276A1 (es)
BR (2) BR112022022433A2 (es)
CA (2) CA3178882A1 (es)
CL (1) CL2022003104A1 (es)
CO (1) CO2022017780A2 (es)
IL (2) IL297981A (es)
MX (2) MX2022013999A (es)
PE (1) PE20230494A1 (es)
TW (1) TW202208414A (es)
WO (2) WO2021226551A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
WO2021128027A1 (zh) * 2019-12-24 2021-07-01 荣昌生物制药(烟台)股份有限公司 TACI-Fc融合蛋白及其用途
AU2022269139A1 (en) * 2021-05-07 2023-11-16 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
WO2023089500A1 (en) * 2021-11-17 2023-05-25 Aurinia Pharmaceuticals Inc. B cell activating factor (baff)-a proliferation inducing ligand (april) dual inhibitors
WO2023236967A1 (zh) * 2022-06-08 2023-12-14 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗重症肌无力的方法
WO2024044721A1 (en) * 2022-08-25 2024-02-29 University Of Washington Injectable recombinant protein-based hydrogels for therapeutic delivery

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5443964A (en) 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
CA2102623C (en) 1991-05-06 2003-04-22 Jeffrey Schlom Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
DE69534702T2 (de) 1994-09-23 2006-08-24 The University Of British Columbia, Vancouver Verfahren zur erhöhung der expression von endogenen peptiden tragenden mhc klasse i molekulen
EP1016418B1 (en) 1994-10-03 2009-12-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Host cell comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP2230307A1 (en) 1996-10-25 2010-09-22 Human Genome Sciences, Inc. Neutrokine alpha
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
EP1102790B1 (en) 1998-08-07 2014-05-07 University of Washington Immunological Herpes Simplex Virus antigens and methods for use thereof
TR200101998T2 (tr) 1999-01-07 2002-06-21 Zymogenetics, Inc. Çözünür reseptör BR 43x2 ve kullanım metodları
US7833529B1 (en) * 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20060067933A1 (en) 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
ES2478635T3 (es) 1999-08-09 2014-07-22 Targeted Genetics Corporation Incremento de la expresión de una secuencia de nucleótidos heteróloga monocatenaria de vectores virales recombinantes diseñando la secuencia de modo que forma pares de bases intracatenarios
DK1255558T3 (da) 2000-02-16 2006-10-23 Genentech Inc Anti-april antistoffer og hybridomaceller
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
DK1297013T3 (da) 2000-04-27 2006-12-27 Biogen Idec Inc Anvendelse af TACI som antitumormiddel
EP1746106A3 (en) 2000-04-27 2007-03-14 Biogen Idec MA Inc. Use of TACI as an anti-tumor agent
US20020086018A1 (en) 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
JP2004533997A (ja) 2001-02-20 2004-11-11 ザイモジェネティクス，インコーポレイティド Ｂｃｍａ及びｔａｃｉの両者を結合する抗体
CA2446734A1 (en) 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
SI1436003T1 (sl) 2001-05-24 2010-02-26 Zymogenetics Inc TACI-imunoglobulinski fuzijski proteini
WO2003014294A2 (en) 2001-08-03 2003-02-20 Genentech, Inc. Tacis and br3 polypeptides and uses thereof
EP1461073B1 (en) 2001-11-30 2010-01-06 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Peptide agonists of prostate-specific antigen, and uses therefor
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CA2492447A1 (en) 2002-07-25 2004-02-05 Genentech, Inc. Taci antibodies and uses thereof
CA2501459A1 (en) 2002-10-11 2004-04-22 Zymogenetics, Inc. Production of homotrimeric fusion proteins
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
KR20060027801A (ko) 2003-06-05 2006-03-28 제넨테크, 인크. Ｂ 세포 장애에 대한 조합 요법
MXPA06004301A (es) 2003-10-20 2006-06-05 Biogen Idec Inc Regimenes terapeuticos para antagonistas del factor de activacion de celulas b.
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
EP1919950A1 (en) 2004-07-15 2008-05-14 Xencor, Inc. Optimized fc variants
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
CA2585927A1 (en) 2004-11-04 2006-05-18 Genentech, Inc. Polypeptides that bind baff and/or april
US7550296B2 (en) 2004-12-01 2009-06-23 Bayer Schering Pharma Ag Generation of replication competent viruses for therapeutic use
JP2008526205A (ja) * 2004-12-31 2008-07-24 ジェネンテック・インコーポレーテッド Ｂｒ３に結合するポリペプチド及びその使用
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EP1922080A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
US20090226440A1 (en) 2005-08-12 2009-09-10 Shane Grey Prophylactic and/or Therapeutic Method for Treatment of Autoimmune Disease
WO2007030803A2 (en) 2005-09-09 2007-03-15 Zymogenetics, Inc. Method for preparing trimeric proteins
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR20140077946A (ko) 2005-10-13 2014-06-24 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
CN101489573B (zh) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
JP2010501622A (ja) 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法
US8513393B2 (en) 2006-08-28 2013-08-20 Ares Trading S.A. Process for the purification of Fc-containing proteins
WO2008025747A1 (en) 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
US20100063257A1 (en) 2007-01-26 2010-03-11 Merck Serono Sa Purification of FC-TACI Fusion Proteins Using the Oilbody Technology
ES2422479T3 (es) 2007-03-27 2013-09-11 Zymogenetics Inc Combinación de inhibición de BLyS y micofenolato de mofetilo para tratamiento de enfermedades autoinmunitarias
JP2010530000A (ja) * 2007-06-13 2010-09-02 ザイモジェネティクス，インコーポレイティド アタシセプトなどのＴＡＣＩ−Ｉｇ融合タンパク質を用いた自己免疫疾患を治療するための投薬法
CN101323643B (zh) 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
EP2200631A1 (en) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
AU2008314689A1 (en) 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying an Fc-containing protein
JP5469077B2 (ja) 2007-11-12 2014-04-09 アレス トレーディング ソシエテ アノニム Ｔａｃｉ−免疫グロブリン融合タンパク質のための調製物
EP2219674A1 (en) 2007-11-12 2010-08-25 Ares Trading S.A. Taci-immunoglobulin fusion proteins for treatment of optic neuritis
US20100261887A1 (en) 2007-11-12 2010-10-14 Ares Trading S.A. Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis
EP3342872A1 (en) 2007-12-11 2018-07-04 The University of North Carolina at Chapel Hill Polypurine tract modified retroviral vectors
WO2009132058A2 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US8003335B2 (en) 2008-04-30 2011-08-23 Universite Paris-SUD11 Levels of APRIL in serum and use in diagnostic methods
WO2009134633A1 (en) 2008-05-01 2009-11-05 Zymogenetics, Inc. Levels of blys/april heterotrimers in serum and use in diagnostic methods
EP2310409A2 (en) 2008-06-17 2011-04-20 Apogenix GmbH Multimeric tnf receptors
WO2010136480A1 (en) 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins
WO2011109280A1 (en) * 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
CN101851278B (zh) 2010-05-26 2013-03-13 石药集团中奇制药技术（石家庄）有限公司 B细胞激活因子拮抗剂及其制备方法与用途
US20110311548A1 (en) 2010-06-18 2011-12-22 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system
WO2012032112A1 (en) 2010-09-10 2012-03-15 Cellerix, S.A. Stem cell culture media and methods
CN102085368B (zh) 2011-01-19 2013-06-12 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用
JP5972915B2 (ja) 2011-03-16 2016-08-17 アムジエン・インコーポレーテツド Ｆｃ変異体
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
HUE033008T2 (hu) 2011-04-13 2017-11-28 Bristol Myers Squibb Co FC fúziós proteinek, amelyek tartalmaznak új linkereket
WO2013041029A1 (en) * 2011-09-23 2013-03-28 Igenimed Pharmaceuticals Inc. Novel soluble ctla4 variants
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
WO2013130684A1 (en) 2012-02-27 2013-09-06 Amunix Operating Inc. Xten-folate conjugate compositions and methods of making same
WO2014126884A1 (en) 2013-02-12 2014-08-21 Bristol-Myers Squibb Company High ph protein refolding methods
EP2956468B1 (en) 2013-02-12 2020-06-10 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
CA2903546A1 (en) 2013-03-15 2014-09-25 Biogen Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
WO2015107026A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
WO2015172305A1 (zh) * 2014-05-12 2015-11-19 上海康岱生物医药技术股份有限公司 抑制taci-baff复合物形成的融合蛋白及其制法和用途
MX2017000630A (es) 2014-07-15 2017-04-27 Immune Design Corp Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
SG10201913682QA (en) 2015-06-25 2020-03-30 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
CR20180318A (es) * 2015-12-14 2018-09-19 Macrogenics Inc Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
KR20190006495A (ko) 2016-04-15 2019-01-18 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
KR20230051602A (ko) 2016-04-15 2023-04-18 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
EP3474867A4 (en) 2016-06-24 2020-05-20 iCell Gene Therapeutics LLC CHIMERIC ANTIGEN (CAR) RECEPTORS, COMPOSITIONS AND RELATED METHODS
CN110088127A (zh) 2016-07-28 2019-08-02 高山免疫科学股份有限公司 Cd155变体免疫调节蛋白及其用途
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
EP3596116B1 (en) 2017-03-16 2023-09-06 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
AU2018235838B2 (en) 2017-03-16 2023-12-14 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
CN110945030A (zh) 2017-06-20 2020-03-31 丹娜法伯癌症研究院 使用april-taci相互作用的调节剂调节调控性t细胞、调控性b细胞和免疫响应的方法
EP3675897A1 (en) 2017-09-01 2020-07-08 Dana Farber Cancer Institute, Inc. Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
EA202090974A1 (ru) 2017-10-18 2020-08-05 Элпайн Иммьюн Сайенсиз, Инк. Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы
GB201720426D0 (en) 2017-12-07 2018-01-24 Hummingbird Bioscience Pte Ltd CD47 and BCMA antigen-binding molecules
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
KR20200128054A (ko) 2018-03-02 2020-11-11 알로젠 테라퓨틱스 인코포레이티드 유도성 키메라 사이토카인 수용체
CN110522908A (zh) 2018-05-25 2019-12-03 荣昌生物制药（烟台）有限公司 TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
WO2020028572A2 (en) 2018-08-01 2020-02-06 Unum Therapeutics Inc. ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF
WO2020047329A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof
WO2020061376A2 (en) 2018-09-19 2020-03-26 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
AU2019377854A1 (en) 2018-11-08 2021-05-27 Juno Therapeutics, Inc. Methods and combinations for treatment and T cell modulation
JP2022510276A (ja) 2018-11-30 2022-01-26 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８６バリアント免疫調節タンパク質およびその使用
MX2021012607A (es) 2019-04-17 2022-03-11 Alpine Immune Sciences Inc Metodos y usos de proteinas de fusion de ligando icos (icosl) variante.
WO2020252421A2 (en) 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
CA3154191A1 (en) 2019-09-13 2021-03-18 Kyowa Kirin Co., Ltd. Dcr3 variant
JP7326500B2 (ja) 2019-12-10 2023-08-15 レメゲン シーオー．，エルティーディー． ＴＡＣＩ－Ｆｃ融合タンパク質医薬品製剤
WO2021128027A1 (zh) 2019-12-24 2021-07-01 荣昌生物制药(烟台)股份有限公司 TACI-Fc融合蛋白及其用途

Also Published As

Publication number Publication date
US20210363223A1 (en) 2021-11-25
EP4146683A1 (en) 2023-03-15
CO2022017780A2 (es) 2023-03-17
CN117736297A (zh) 2024-03-22
CN116194467A (zh) 2023-05-30
WO2021226553A3 (en) 2022-04-28
KR20230029621A (ko) 2023-03-03
BR112022022524A2 (pt) 2022-12-13
CA3178885A1 (en) 2021-11-11
CA3178882A1 (en) 2021-11-11
JP2023525033A (ja) 2023-06-14
WO2021226551A1 (en) 2021-11-11
JP2023525032A (ja) 2023-06-14
TW202208414A (zh) 2022-03-01
AU2021268033A1 (en) 2022-12-15
WO2021226553A2 (en) 2021-11-11
CN115812077A (zh) 2023-03-17
US11274140B2 (en) 2022-03-15
CN116903727A (zh) 2023-10-20
EP4146684A2 (en) 2023-03-15
US20210388054A1 (en) 2021-12-16
MX2022013998A (es) 2023-02-16
CL2022003104A1 (es) 2023-07-14
KR20230029622A (ko) 2023-03-03
AU2021267276A1 (en) 2022-12-15
MX2022013999A (es) 2023-02-16
BR112022022433A2 (pt) 2022-12-13
IL297980A (en) 2023-01-01
IL297981A (en) 2023-01-01
US20230241168A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
PE20230494A1 (es) Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas
EA200702346A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
CY1111469T1 (el) ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ 3-ΦΑΙΝΥΛΘΕΙΟ-1Η-ΙΝΔΟΛΗ-1-ΟΞΙΚΟΥ ΟΞΕΟΣ ΩΣ ΡΥΘΜΙΣΤΕΣ ΤΗΣ ΔΡΑΣΗΣ ΤΟΥ ΥΠΟΔΟΧΕΑ CRTh2
CR9591A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
ATE509030T1 (de) Reinigung von fibrinogen
EA200200590A1 (ru) Производные пирролидина в качестве ингибиторов фосфодиэстеразы, специфичной к циклическому амф
BR0315234A (pt) Derivados de indol como agonistas beta-2
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
EA200601861A1 (ru) ПОЛИПЕПТИДЫ TACIs И BR3 И ИХ ПРИМЕНЕНИЕ
EA200601239A1 (ru) Замещённые хинолиновые соединения
UY30732A1 (es) Compuestos para la modulacion de la actividad del c-fms y/o el c-kit y sus usos aplicables
EA200501667A1 (ru) Рецепторный комплекс тканезащитных цитокинов, способы идентификации тканезащитных соединений и их применение
BRPI0513915A (pt) compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
ME00356B (me) Novi peptidi koji se vezuju za receptor eritropoietina
NO20045589L (no) Nye forbindelser
BRPI0511111A (pt) compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários
BRPI0414593A (pt) derivados de ácido sulfonamida substituìda-indol-2-carboxìlico como inibidores de pai-1
EA200801068A1 (ru) Производные четвертичного альфа-аминокарбоксамида в качестве модуляторов потенциалозависимых натриевых каналов
DE602005022099D1 (de) Fluorisierungsverfahren zur synthese von 2-ä18fü fluoro-2-deoxy-d-glukose
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
AR023848A1 (es) Glicoproteina vi recombinante del receptor de colageno sobre plaquetas y su uso farmaceutico
CO2023016161A2 (es) Métodos de dosificación y tratamiento con una proteína inmunomoduladora de fusión taci-fc
NO20074639L (no) Krystallinsk base av trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
ATE420167T1 (de) Reinigungsverfahren für plasmid-dna
CR7735A (es) Piperizinas heterociclicas sustituidas para el tratamiento de la esquizofrenia